Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087022 · ClinicalTrials.gov registry record · Phase 3
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Phase 3 study, sponsored by Heidelberg Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 864
- Enrollment target
NCT00087022: Completed Phase 3 study, sponsored by Heidelberg Pharma.
NCT00087022 is a Phase 3 study that has completed, run by Heidelberg Pharma. The registered enrollment target is 864 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087022, a Phase 3 study, has completed, sponsored by Heidelberg Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 864 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether monoclonal antibody therapy is effective in treating kidney cancer. PURPOSE: This randomized phase III trial is studying monoclonal antibody therapy to see how well it works in treating patients who have undergone surgery for nonmetastatic primary kidney cancer.
Interventions
- OTHER placebo
- BIOLOGICAL girentuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 864 participants |
| Start Date | 2004-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087022
The ClinicalTrials.gov registry entry for NCT00087022 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 864 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heidelberg Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00087022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087022 about?
NCT00087022 is a clinical study titled "Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether monoclonal antibody therapy is effective in treating kidney cancer. PURPOSE: This randomized phase III trial is studying...
What is the current status of trial NCT00087022?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 864 participants. The study started on 2004-07. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00087022?
The interventions under investigation include: placebo (OTHER), girentuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00087022?
This trial is sponsored by Heidelberg Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.